Sarepta Therapeutics’ (SRPT) “Sell” Rating Reiterated at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating restated by investment analysts at HC Wainwright in a research note issued on Monday, Marketbeat reports. They currently have a $5.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential downside of 71.57% from the company’s previous close.

A number of other research firms have also weighed in on SRPT. JPMorgan Chase & Co. lowered their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, July 9th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. William Blair upgraded Sarepta Therapeutics to a “hold” rating in a research report on Wednesday, September 23rd. Finally, Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, September 28th. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and eight have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $22.71.

Sarepta Therapeutics Price Performance

SRPT traded up $0.28 during trading on Monday, hitting $17.59. The company’s stock had a trading volume of 638,914 shares, compared to its average volume of 3,047,301. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a twelve month low of $14.68 and a twelve month high of $25.32. The business’s fifty day simple moving average is $19.06 and its 200 day simple moving average is $18.82. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -6.08, a P/E/G ratio of 0.27 and a beta of 0.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.Sarepta Therapeutics’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same period last year, the company earned $2.02 earnings per share. On average, equities research analysts forecast that Sarepta Therapeutics will post 3.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. grew its position in Sarepta Therapeutics by 7.8% during the first quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 636 shares during the period. Public Employees Retirement System of Ohio grew its position in Sarepta Therapeutics by 3.1% during the first quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 875 shares during the period. Baird Financial Group Inc. grew its position in Sarepta Therapeutics by 7.6% during the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 901 shares during the period. Meeder Asset Management Inc. purchased a new stake in Sarepta Therapeutics during the second quarter valued at about $27,000. Finally, Rockefeller Capital Management L.P. grew its position in Sarepta Therapeutics by 98.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock valued at $88,000 after acquiring an additional 2,034 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.